Skip to content

Use of the ECG Watch in Palpitation Assessment: Feasibility Study

Use of the ECG Watch in Palpitation Assessment: Feasibility Study

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07121816
Acronym
WATCH-RHYTHM
Enrollment
120
Registered
2025-08-14
Start date
2025-09-01
Completion date
2028-09-01
Last updated
2025-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Palpitation

Keywords

Palpitations, ScanWatch (Withings®), ECG

Brief summary

Palpitations are the cause of 16% of reasons for consultation with the general practitioner. 41% of palpitations are secondary to cardiac arrhythmia. If a rhythm or conduction disorder is recorded in a symptomatic context, then the cardiac origin can be validated or invalidated. The challenge therefore consists of obtaining an ECG trace during an attack of palpitations (per-critical ECG). Since patients are rarely symptomatic during consultations, additional exploration by ambulatory electrocardiographic recording is essential. To date, the 24-hour Holter ECG is currently the most used in current practice, only has a sensitivity of 22 to 35% maximum depending on the studies. We hypothesize that the ECG watch is a reliable medical tool in the etiological assessment of palpitations, with at least 90% of traces interpretable. The main objective of this study is to validate the use of the ScanWatch watch (Withings®) in the assessment of palpitations.

Detailed description

The following examinations will be carried out: * After inclusion: Information on the operation of the connected watch, loan of the watch, and implementation of a 14-day Spider Flash. * For a minimum of 14 days to 1 month, the patient will wear the connected watch, and activate it during an attack of palpitations. For 14 days, he will be concomitantly equipped with a Spider Flash. * All of the watch's traces will be automatically transferred to the Withings RPM data visualization platform independent of each center. The traces will then be centralized anonymously to analyze the results. * At the end of the loan period, the patient then returns the watch to the cardiology department of their reference center. The Spider Flash is removed after 14 days. * The patient will be summoned to carry out additional examinations or make therapeutic modifications according to the results of these examinations as part of routine care by their reference center.

Interventions

DEVICEECG watch

ECG watch in palpitation assessment

Sponsors

Hôpital Haut-Lévêque
CollaboratorOTHER
University Hospital, Toulouse
CollaboratorOTHER
University Hospital, Clermont-Ferrand
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

ScanWatch (Withings®) For a minimum of 14 days to 1 month, the patient will wear the connected watch, and activate it during an attack of palpitations. For 14 days, he will be concomitantly equipped with a Spider Flash.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patient, male or female, referred for cardiological consultation for assessment of palpitations, after which an outpatient electrocardiographic exploration is carried out by the cardiologist. * \- Patient presenting at least 1 palpitation attack per month over the last 3 months or at least 1 palpitation attack per week over the last month. * Patient equipped with a smartphone compatible with the HealthMate application. * Able to give consent to participate in research. * Affiliation to a social security regime.

Exclusion criteria

: * Patient physically or mentally unable to make a recording using the connected watch. * Patient contraindicated for the application of skin patches. * Patient with pacemaker or defibrillator. * Pregnant or breastfeeding women * Patients of legal age under protective supervision * Refusal to participate

Design outcomes

Primary

MeasureTime frame
Concordance between the number of per-critical tracings obtained via the connected watch (explanatory variable) and the number of interpretable tracings obtained (dependent variable)One month

Secondary

MeasureTime frameDescription
Average number of traces per critical necessary to obtain an interpretable trace with the Spider Flash and the connected watch.One month
Average time to obtain a per critical traceOne month
Classification of recorded eventsOne monthDevice events Cardiovascular events

Countries

France

Contacts

Primary ContactLise LACLAUTRE
promo_interne_drci@chu-clermontferrand.fr+33473754963

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026